This post was originally published on this site The Arthur M. Blank Family Foundation has given $1 million to the Icahn School of Medicine at Mount Sinai‘s urology department to support research into prostate cancer. Together with an earlier foundation gift of $500,000, the money will support the New York school’s Prostate Cancer Program, whose mission is to…
Conditions
Conditions
Health Canada Approves Adcetris-Chemo Combo for Initial Peripheral T-cell Lymphoma Treatment
This post was originally published on this site Health Canada has expanded its approval of Adcetris (brentuximab vedotin) in combination with a chemotherapy regimen for the first-line treatment of peripheral T-cell lymphomas expressing the CD30 marker. The approval is for Adcetris in combination with CHP (cyclophosphamide, doxorubicin, prednisone) chemotherapy, and is for people with previously untreated…
MGUS Patients Have More Frequent Hospital Visits Prior to Diagnosis than Healthy Controls, Research Shows
This post was originally published on this site People with monoclonal gammopathy of undetermined significance (MGUS), a rarely diagnosed condition that can progress to myeloma, go to the hospital twice as often as people without the condition, new research suggests. This may be helpful in identifying people with MGUS and, by extension, aid in early…
NICE Recommends Lynparza Tablets for Relapsed, BRCA-mutated Advanced Ovarian Cancers
This post was originally published on this site After an initial rejection due to cost-effectiveness concerns, the U.K.’s National Institute of Health and Care Excellence (NICE) has reversed its decision and is expanding the use of Lynparza (olaparib) tablets to include maintenance therapy for relapsed ovarian cancer patients who responded to platinum-based chemotherapy. The recommendation is…
Phase 1 Trial for Potential Alzheimer’s Therapy Yields Positive Results
This post was originally published on this site A recent Phase 1 clinical study of a potential Alzheimer’s therapy showed positive results regarding both safety and biomarkers for cognitive processes. The data support advancing the investigational compound, NDX-1017, developed by Athira Pharma, to later-stage clinical trials. The results, “Phase 1 Study of NDX-1017: Safety, Pharmacokinetics and…
Holiday Travel Is Possible in Early Stages of Alzheimer’s
This post was originally published on this site A record number of people are expected to travel this holiday season. The travelers will undoubtedly include familial caregivers journeying with loved ones who have dementia. These are courageous individuals, perhaps seeking one last hurrah before Alzheimer’s disease prevents them from traveling to faraway destinations. Taking a…
Bemcentinib-Keytruda Combo Effective in Some Advanced NSCLC Patients with Poor Prognosis
This post was originally published on this site Combining bemcentinib with Keytruda (pembrolizumab) is effective and delays disease progression in people with previously treated advanced non-small cell lung cancer (NSCLC), particularly in those with AXL-positive tumors. Those updated results from a Phase 2 clinical trial show, to researchers’ surprise, that benefits also were seen in people with low levels of PD-L1…
Nuplazid ‘Encouraging’ in Lowering Dementia-related Psychosis Risk, HARMONY Trial Finds
This post was originally published on this site [Editor’s note: This story, published on Dec. 10, was updated on Dec. 16 with additional details provided by Acadia Pharmaceuticals.] People with Alzheimer’s and other dementias treated with Nuplazid (pimavanserin) in a Phase 3 trial were almost three times less likely to have a psychosis relapse —…
Breast Cancer Index Identifies Women Likely to Benefit From Extended Hormone Therapy, Latest Data Show
This post was originally published on this site The Breast Cancer Index, a molecular test developed by Biotheranostics, successfully identified a group of women with hormone receptor (HR)-positive breast cancer who may benefit from long-term hormone therapy with tamoxifen, data from a Phase 3 trial shows. Study findings were presented in a poster, titled “Breast…
Advanced Multiple Myeloma Patients Responding to Janssen’s CAR T-cell Therapy, Trial Data Show
This post was originally published on this site Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528 (JNJ-68284528), safely led to early and deep responses in all patients with relapsed or refractory multiple myeloma treated in the first part of a Phase 1/2 trial. These findings were announced in the oral presentation, “Results from…
AFA Seeks Essays from Teens for its Alzheimer’s Awareness College Scholarship Contest
This post was originally published on this site With its annual essay competition, the Alzheimer’s Foundation of America (AFA) is again offering high schoolers affected by Alzheimer’s disease a chance to motivate others and earn money for college. In the AFA Teens for Alzheimer’s Awareness College Scholarship Essay Contest, college-bound high school seniors nationwide are invited…
Meeting with FDA Supports Tazemetostat for Some Follicular Lymphoma
This post was originally published on this site Epizyme successfully met with the U.S. Food and Drug Administration (FDA) to bolster an upcoming submission of its oral investigational treatment tazemetostat for relapsed or resistant follicular lymphoma, with or without EZH2 activating mutations. The pre-New Drug Application (NDA) meeting is a critical step to ensure a…